1.

Record Nr.

UNINA9910964417803321

Autore

Albertson Stephanie L (Stephanie Lynn), <1971->

Titolo

The effect of jurors' race on their response to scientific evidence / / Stephanie L. Albertson

Pubbl/distr/stampa

El Paso, Tex., : LFB Scholarly Pub., c2012

ISBN

9781593325121

1593325126

Edizione

[1st ed.]

Descrizione fisica

1 online resource (174 p.)

Collana

Criminal justice : recent scholarship

Disciplina

347.73/67

Soggetti

Jurors - United States - Decision making

Discrimination in criminal justice administration - United States

Jurors - United States - Attitudes

Evidence, Criminal - United States

Evidence, Expert - United States

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

The importance of jurors' race -- The impact of attitude formation on jury decision making -- Background : the science of DNA and the use of complex scientific evidence in the courts -- Scientific evidence and juror comprehension -- An analysis of jurors' race and education -- Summary of findings : the need for reform.

Sommario/riassunto

Albertson seeks to analyze the influence of jurors' race on perceptions of complex scientific evidence. Jury eligible citizens viewed a mock criminal trial involving the presentation of mitochondrial deoxyribonucleic acid (mtDNA). White and African American mock jurors' perceptions of mtDNA were measured. Although robust findings were discovered regarding race, results imply that an educational background in science and math is important. The present study has shown the negative impact that low levels of science and math courses have on perceptions of scientific evidence. Courtroom evidence wi



2.

Record Nr.

UNINA9910968604203321

Titolo

Evolution of translational omics : lessons learned and the path forward / / Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Board on Health Care Services; Board on Health Sciences Policy ; Christine M. Micheel, Sharyl J. Nass, and Gilbert S. Omenn, editors ; Institutes of Medicine of the National Academies

Pubbl/distr/stampa

Washington, D.C., : National Academies Press, c2012

ISBN

1-283-63640-9

0-309-22419-5

Edizione

[1st ed.]

Descrizione fisica

1 online resource (338 p.)

Altri autori (Persone)

MicheelChristine

NassSharyl J

OmennGilbert S

Disciplina

572.33

Soggetti

Genomics - Technology

Genomics - Data processing

Genetic translation - Technology

Biomolecules - Analysis

Biomolecules - Data processing

Bioinformatics - Technology

Biotechnology

Data mining - Analysis

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references.

Nota di contenuto

""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 Omics-Based Clinical Discovery: Science, Technology, and Applications""; ""3 Best Practices for Omics-Based Test Validation Prior to Use for Patient Management Decisions in a Clinical Trial Setting""; ""4 Evaluation of Omics-Based Tests for Clinical Utility and Use""; ""5 Responsible Parties""; ""6 Lessons from the Case Studies""; ""Appendix A: Case Studies""



""Appendix B: Gene Expression Based Tests Developed at Duke University and Used in Clinical Trials""""Appendix C: Introduction to Biomarkers""; ""Appendix D: Reporting Guidelines""; ""Appendix E: Committee Member and Staff Biographies""; ""Appendix F: Information Gathering Sessionsand Speakers""; ""Acronyms and Abbreviations""; ""Glossary""

Sommario/riassunto

Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.